3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
20
Lymphoma
6
Urinary Bladder Neoplasms
3
Urothelial Carcinoma of the Bladder
1
Rhabdoid Tumor
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Choroid Plexus Neoplasms
1
Childhood Solid Tumor
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Astrocytoma
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Vinblastine
×
1 year
×
Clear all
No trials found.